Rali Aniket S, Sauer Andrew J
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Baylor College of Medicine Houston, Texas.
Division of Advanced Heart Failure and Heart Transplantation, Department of Cardiovascular Medicine, University of Kansas Health System Kansas City, Kansas.
US Cardiol. 2020 Mar 25;14:e01. doi: 10.15420/usc.2020.14. eCollection 2020.
There seems to be a unique interplay between 2019 novel coronavirus (SARS-CoV-2) and cardiovascular diseases, although it is predominantly a respiratory illness. Patients with pre-existing cardiovascular co-morbidities appear to be at highest risk for mortality from coronavirus disease 2019 (COVID-19) along with the elderly; COVID-19 also contributes to cardiovascular complications, including acute coronary syndromes, arrhythmias, myocarditis, acute heart failure, and, in the most severe cases, cardiogenic shock and death. Several medications proposed in the treatment of COVID-19 require cardiac monitoring owing to their cardiac-specific adverse effects. Ultimately, the COVID-19 pandemic has jeopardized the safety of heart transplantation and has placed transplant recipients on immunosuppressive therapies at significant risk. In this article, the authors summarize the rapidly emerging data on the cardiovascular implications of SARS-CoV-2 and COVID-19.
2019新型冠状病毒（SARS-CoV-2）与心血管疾病之间似乎存在一种独特的相互作用，尽管它主要是一种呼吸道疾病。患有心血管合并症的患者与老年人一样，似乎是2019冠状病毒病（COVID-19）死亡风险最高的人群；COVID-19还会引发心血管并发症，包括急性冠状动脉综合征、心律失常、心肌炎、急性心力衰竭，在最严重的情况下，还会导致心源性休克和死亡。由于其特定于心脏的不良反应，几种用于治疗COVID-19的药物需要进行心脏监测。最终，COVID-19大流行危及心脏移植的安全性，并使接受免疫抑制治疗的移植受者面临重大风险。在本文中，作者总结了关于SARS-CoV-2和COVID-19对心血管影响的迅速涌现的数据。
